Trial Profile
Phase II Study of Ramucirumab With Trastuzumab and Capecitabine/Cisplatin in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary) ; Capecitabine; Cisplatin; Trastuzumab
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 06 Jan 2020 Status changed from completed to discontinued.
- 27 Feb 2019 Status changed from active, no longer recruiting to completed.
- 15 Feb 2019 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.